The effect of intravenous midazolam on persistent postoperative nausea and vomiting (PONV) was compared to placebo in a prospective randomized double-blind study. Twenty patients aged 18 to 82 years with persistent PONV resistant to standard anti-emetics and present for greater than six hours were randomized to receive either an intravenous infusion of midazolam 1.0 mg/h or placebo. Nausea (P=0.04), vomiting (P=0.02) and the use of rescue antiemetics (P=0.003) were significantly less in the midazolam group. We conclude that low-dose intravenous infusion of midazolam significantly reduces persistent PONV.
One of the most unpleasant side-effects of surgery and anaesthesia is postoperative nausea and vomiting (PONV). Its incidence is commonly quoted as being between 20 to 30% 1,2 , however, it can occur in up to 85% in some surgical patients 3 . The majority of these patients respond to conventional anti-emetics, but a small number may suffer prolonged PONV which is resistant to both established and newer anti-emetics. Even combinations of arguably the most effective anti-emetics droperidol and ondansetron do not reduce PONV rates to zero 4 .
Benzodiazepines, including midazolam, have been shown to be effective in chemotherapy induced nausea and vomiting 5 . In a previous series of three cases we recently found that low-dose intravenous infusion of midazolam was beneficial in persistent PONV 6 .
The aim of this current study was to examine the effect of an intravenous midazolam infusion on a subgroup of patients with resistant and prolonged PONV.
METHODS
Over an 18 month period, 20 patients were recruited to the study which was approved by the Human Rights Committee at the University of Western Australia. Following written informed consent, patients who were still suffering from nausea and vomiting six hours following surgery and at least two hours after their last anti-emetic administration (Table 1) , as prescribed by their anaesthetist, were offered entry to the study. Patients under the age of 18 years, pregnant women and those unable to comprehend written and spoken English were excluded.
From a table of random numbers, patients were given intravenously either normal saline or midazolam. Blinded 100 ml bags were made available from the hospital pharmacy. Both groups received 10 ml of the solution as a bolus over 10 minutes and then a continuous infusion of 10 ml per hour for nine hours. (Midazolam concentration 0.1 mg/ml, i.e. 10 mg in 100 ml, the saline group receiving 0.9% saline.)
All patients received oxygen 4 l/min by mask, pulse oximetry (S P 0 2 ) and ventilatory rate were recorded hourly. Nausea (no nausea=0, mild nausea=1, severe nausea=2) and sedation (wide awake=1, eyes open, drowsy=2, eyes closed easily roused=3, difficult to rouse=4, unrousable=5) scores, together with the number of vomits/dry retches were recorded hourly. Both groups were offered rescue anti-emetics which had been already prescribed by their anaesthetist.
The sedation and nausea scores for each group of patients were summed (cumulative scores). Statistical evaluation was carried out using the Pearson Chi square with Fisher exact test because of low numbers and the Mann-Whitney U test. A P value <0.05 was considered significant.
RESULTS
There were 10 patients in each group, the demographic and analgesic data together with the pre-trial anti-emetics used is shown in Table 1 . No significant differences were found between the groups with regard to age, sex, surgical procedure, analgesic techniques or pre-trial anti-emetic use.
There was no clinically significant difference in sedation score or change in S P 0 2 in either the saline or midazolam groups (Table 2 ) however, one patient in each group became confused and disoriented and their infusions were ceased early.
Patients in the midazolam group had significantly smaller cumulative nausea scores (P=0.040) and number of vomits (P=0.02). Rescue anti-emetics were only required in the placebo group (P=0.003) ( Table 2) .
DISCUSSION
Assessing postoperative nausea and vomiting can be difficult because of the range of factors that are involved and as a result of this, designing trials that examine the efficacy of anti-emetics can be equally difficult 7 .
The incidence of PONV appears to have fallen since the days of ether anaesthesia. This may be due to the introduction of new anaesthetic techniques and more effective anti-emetic agents; however, it continues to be a distressing feature of anaesthesia and surgery for some patients 8 .
We have identified a group of patients who did not respond to conventional anti-emetics and who continued to be distressed by PONV at six hours following termination of their anaesthesia. This group of patients has been classified by other investigators as having "severe PONV" 9 or "persistent PONV" 8 . There are no clear data on the incidence of symptoms in this small subgroup of PONV but Forrest has suggested an incidence of 0.1% after all anaesthesia 9 . The calculated sample size required for a power of 80% was 20 patients in each group and our randomization schedule was therefore arranged in blocks of 20. Because of the clinical and statistically significant difference when the first block was completed and the eighteen-month period that was required to collect the patients, the trial was terminated. Excluded from this group are those patients that respond to an anti-emetic but have a recurrence of PONV when the effects of the drug wear off. These patients are readily treated with a second dose of their original anti-emetic. The newer anti-emetic agents such as the 5HT3 antagonists even in combination with drugs such as droperidol do not reduce the incidence of PONV to zero 10 .
We have previously suggested that midazolam may have a role in the management of PONV 6 . This current study has confirmed that a low-dose midazolam infusion significantly reduces nausea and vomiting. The continued request for rescue anti-emetic in the placebo group (Table 2) was also noted in a study by Gilliland. Gilliland's study, designed to demonstrate the morphine-sparing effect of midazolam, showed that the group receiving the midazolam infusion (1 mg/70kg/hour) had significantly lower anti-emetic requirements compared to the placebo group, however, the incidence of nausea and vomiting did not differ significantly between their two groups.
The safety of low-dose midazolam infusion in combination with opioids has been demonstrated previously 11, 12 and is supported by our study which found no difference between the groups with respect to SP0 2 or sedation scores. The anaesthetic drugs and techniques which are important in the establishment of PONV could not be controlled in this study because recruitment occurred late in the postoperative period. However, although pain scores and opioid dose were not recorded, other variables such as the type of procedure, analgesic technique employed, gender and pretrial anti-emetic were not Care, Vol. 27, No. 1, February 1999 different between the groups ( Table 1) . The mechanism of action of the anti-emetic effect of midazolam is not well understood. It has been postulated that midazolam causes a reduction in anxiety and a decrease in dopaminergic input to the chemoreceptor trigger zone (CRTZ) 6. Midazolam may reduce the reuptake of adenosine. This leads to an adenosine-mediated reduction in synthesis, release and postsynaptic action of dopamine at the CRTZ. Gamma-amino-butyric acid (GABA)-ergic neurones are also thought to exert an inhibitory effect on central dopaminergic pathways 13 . It may be that benzodiazepines reduce dopaminergic neuronal activity by binding to the GABA A -benzodiazepine receptor complex 15 .
Benzodiazepines may also reduce 5HT release by binding to the GABA A -benzodiazepine receptor complex 16 . Midazolam allosterically inhibits the function of 5HT3 receptors at relatively high doses. This may not be relevant to the action of low-dose midazolam 17 .
PONV is a multifactorial problem, so it is likely that combination therapy with three or four drugs acting via different receptors will be required 10, 18 .
In conclusion, we have found low-dose midazolam infusion to be a safe and effective treatment for resistant PONV. The numbers of patients in this trial were small and therefore further study will be required to substantiate these findings and evaluate the role of midazolam infusion in combination with other anti-emetics.
